Anna V Durbin, 461320 Lowman St, Baltimore, MD 21230

6410023, Jun 25, 2002

Jul 9, 1999

09/350821

Anna P. Durbin - Takoma Park MD
Peter L. Collins - Rockville MD
Brian R. Murphy - Bethesda MD

United States of America - Washington DC

A61K 3912

4241861, 4241841, 4241851, 4241991, 4242111, 4242121, 435 691, 435440, 4352523, 4353201

Recombinant parainfluenza virus (PIV) are provided in which expression of the C, D and/or V translational open reading frame(s) (ORFs) is reduced or ablated to yield novel PIV vaccine candidates. Expression of the C, D and/or V ORF(s) is reduced or ablated by modifying a recombinant PIV genome or antigenome, for example by introduction of a stop codon, by a mutation in an RNA editing site, by a mutation that alters the amino acid specified by an initiation codon, or by a frame shift mutation in the targeted ORF(s). Alternatively, the C, D and/or V ORF(s) is deleted in whole or in part to render the protein(s) encoded thereby partially or entirely non-functional or to disrupt protein expression altogether. C, D and/or V ORF(s) deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These deletion and knock out mutations changes specify one or more desired phenotypic changes in the resulting virus or subviral particle.

2019019, Jun 27, 2019

Mar 11, 2017

16/083652

- Bethesda MD, US
- Baltimore MD, US
Anna P. Durbin - Takoma Park MD, US
Alexander G. Pletnev - Gaithersburg MD, US
Konstantin A. Tsetsarkin - Gaithersburg MD, US

The United States of America, as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD
The Johns Hopkins University - Baltimore MD

C07K 14/005
A61K 39/12

The present disclosure relates to attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and to multivalent immunogenic compositions comprising Zika vaccines and vaccines to other flaviviruses. The chimeric Zika viruses includes a first nucleotide sequence encoding at least one structural protein from a Zika virus (ZIKV), a second nucleotide sequence encoding at least one nonstructural protein from a first flavivirus, and a third nucleotide sequence of a 3′ untranslated region from a second flavivirus. The multivalent immunogenic compositions comprise an attenuated ZIKV vaccine or an attenuated chimeric ZIKV vaccine (or their combination) together with one or more of a first attenuated virus that is immunogenic against dengue serotype 1, a second attenuated virus that is immunogenic against dengue serotype 2, a third attenuated virus that is immunogenic against dengue serotype 3, and a fourth attenuated virus that is immunogenic against dengue serotype 4. The present disclosure further relates to methods of inducing immune responses, as well as preventing or treating ZIKV infections, and in certain embodiments, the combined prevention or treatment of ZIKV and another flavivirus, e.g., dengue virus.